Rami Doukky to Myocardial Perfusion Imaging
This is a "connection" page, showing publications Rami Doukky has written about Myocardial Perfusion Imaging.
Connection Strength
9.349
-
Impact of change of ischemic burden on the outcomes of ESRD patients awaiting kidney transplantation. J Nucl Cardiol. 2023 10; 30(5):1897-1903.
Score: 0.743
-
The Prognostic Value of MPI in CKD: Can we do better? J Nucl Cardiol. 2022 Feb; 29(1):155-157.
Score: 0.637
-
The diagnostic and prognostic value of near-normal perfusion or borderline ischemia on stress myocardial perfusion imaging. J Nucl Cardiol. 2022 04; 29(2):826-835.
Score: 0.621
-
The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging. J Nucl Cardiol. 2022 04; 29(2):810-821.
Score: 0.621
-
Ischemia and Viability Testing in New-Onset Heart Failure. Curr Cardiol Rep. 2020 07 06; 22(8):76.
Score: 0.610
-
The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. J Nucl Cardiol. 2022 Feb; 29(1):101-110.
Score: 0.610
-
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. J Nucl Cardiol. 2018 02; 25(1):137-149.
Score: 0.495
-
The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging. J Nucl Cardiol. 2018 08; 25(4):1313-1323.
Score: 0.482
-
Impact of integrating heart rate response with perfusion imaging on the prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2017 10; 24(5):1666-1671.
Score: 0.459
-
Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging. J Nucl Cardiol. 2017 10; 24(5):1571-1578.
Score: 0.459
-
The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2017 02; 24(1):112-118.
Score: 0.442
-
Impact of insurance carrier, prior authorization, and socioeconomic status on appropriate use of SPECT myocardial perfusion imaging in private community-based office practice. Clin Cardiol. 2015 May; 38(5):267-73.
Score: 0.426
-
Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging. J Nucl Cardiol. 2015 Aug; 22(4):700-13.
Score: 0.425
-
The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99m myocardial perfusion SPECT. J Nucl Cardiol. 2015 Jun; 22(3):526-34.
Score: 0.423
-
Effective risk stratification of patients on the basis of myocardial perfusion SPECT is dependent on appropriate patient selection. Curr Cardiol Rep. 2015 Jan; 17(1):549.
Score: 0.416
-
The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial. J Nucl Cardiol. 2014 Jun; 21(3):496-502.
Score: 0.392
-
The prognostic value of transient ischemic dilatation with otherwise normal SPECT myocardial perfusion imaging: a cautionary note in patients with diabetes and coronary artery disease. J Nucl Cardiol. 2013 Oct; 20(5):774-84.
Score: 0.378
-
The prognostic value of cardiac SPECT performed at the primary care physician's office. J Nucl Cardiol. 2013 Aug; 20(4):519-28.
Score: 0.367
-
Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial". J Nucl Cardiol. 2012 Jun; 19(3):448-57.
Score: 0.342